MDD
50
10
12
23
Key Insights
Highlights
Success Rate
96% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
2.0%
1 terminated out of 50 trials
95.8%
+9.3% vs benchmark
16%
8 trials in Phase 3/4
43%
10 of 23 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 23 completed trials
Clinical Trials (50)
Inhaled DMT for Major Depressive Disorder
Cancer Related Major Depression Treated With a Single Dose of Psilocybin
NUTRIMOOD-Inflammation and Depressive Comorbidity in Obesity: Modulation by Omega-3 Polyunsaturated Fatty Acids Status
Determine the Bioavailability of Selegiline TDS 6mg/24 Hours vs EMSAM in Healthy Subjects
Dynamic Network Response to TMS Treatment
Individualized Neuromodulation for Anhedonic Depression
Theta Burst Stimulation for Refractory Depression in Autism Spectrum Disorder
At-Home tDCS as Maintenance Therapy
Psilocybin rTMS for Treatment Resistant Depression
Extended Reality Behavioral Activation: An Intervention for Major Depressive Disorder
Resonant Frequency rTMS: A Novel Approach to Target Circuit Modulation in Major Depressive Disorder
Neurofeedback to Treat Depression
Feasibility of Home-Based Intermittent 60Hz Light Therapy for Major Depressive Disorder (MDD)
Efficacy of Statins Among Major Depressive Disorder
The MOOD Study - External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for the Treatment of Major Depressive Disorder (MDD)
Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents
Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD
Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition (XanaCIDD)
A Retrospective Study to Evaluate NeuroStar® Advanced Therapy in Adolescents
Mechanism of Action of tACS for the Treatment of MDD